About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01237067

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Study identifier: NCT01237067
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)

Eligibility:

Patients with recurrent/refractory breast cancer that is metastatic or unresectable and for which standard therapies do not exist or are no longer effective. BRCA1/2 mutation carriers will be eligible with any metastatic disease.

Type of study:

Phase I study

Treatment:

Breast cancer patients who enroll will receive one of several possible schedules of olaparib plus carboplatin.

Study site:

Maryland

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Contact: Laura D.Otten, R.N., B.S.N., O.C.N.
Medical Oncology Referral Coordinator 301-451-1228
1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

 

Page updated 03/21/11

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org